← Leaderboards
Piro Lito
Sloan-Kettering Inst Can Research
$7,764,457
Attributed
$7,764,457
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,764,457 · 4
By mechanism
R01$6,891,958 · 3
K08$872,499 · 1
Top collaborators
No co-investigators on record.
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Neal X Rosen$1,689,713
- Eli Lous Diamond$2,748,184
- David B. Solit$21,393,031
- Scott W Lowe$63,222,126
- Michael Stephen Glickman$43,477,930
Others in their field
Top investigators on “Signal Transduction”
- Peter B. Gilbert · Fred Hutchinson Cancer Center$148,539,615
- David Heimbrook · Leidos Biomedical Research, Inc.$82,049,940
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$70,290,471
- Garret A Fitzgerald · University Of Pennsylvania$66,142,222
- Michael Barry Kastan · Duke University$64,512,357
- Randall J Bateman · Washington University$62,939,456
Research focus
Signal TransductionMalignant Neoplasm Of LungMutantMutationPharmaceutical PreparationsCancer CellInnovationMalignant NeoplasmsCellsClinical TrialsResistanceTumor GrowthScienceSuccessKras2 GeneMediatingTumorBaseNf1 GeneInsightPreventBiochemicalAntitumor EffectOncoproteins
Grant awards (21)
Mechanisms of adaptation and resistance to emerging therapies for lung cancer$514,185
R01 · FY2025 · CA · contact PI
Dissecting KRAS oncoprotein signaling with small molecule inhibitors$442,500
R01 · FY2025 · CA · contact PI
Mechanisms of adaptation and resistance to emerging therapies for lung cancer$488,477
R01 · FY2024 · CA · contact PI
Dissecting KRAS oncoprotein signaling with small molecule inhibitors$420,375
R01 · FY2024 · CA · contact PI
Mechanisms of adaptation and resistance to emerging therapies for lung cancer$514,185
R01 · FY2023 · CA · contact PI
Dissecting KRAS oncoprotein signaling with small molecule inhibitors$442,500
R01 · FY2023 · CA · contact PI
Studies on the effects of a novel intermittent therapy on intratumoral clonal architecture and resistance$402,618
R01 · FY2023 · CA · contact PI
Dissecting KRAS oncoprotein signaling with allele specific inhibitors$410,835
R01 · FY2022 · CA · contact PI
Studies on the effects of a novel intermittent therapy on intratumoral clonal architecture and resistance$410,835
R01 · FY2022 · CA · contact PI
Studies on the effects of a novel intermittent therapy on intratumoral clonal architecture and resistance$410,835
R01 · FY2021 · CA · contact PI
Dissecting KRAS oncoprotein signaling with allele specific inhibitors$410,835
R01 · FY2021 · CA · contact PI
Dissecting KRAS oncoprotein signaling with allele specific inhibitors$410,835
R01 · FY2020 · CA · contact PI
Studies on the effects of a novel intermittent therapy on intratumoral clonal architecture and resistance$410,835
R01 · FY2020 · CA · contact PI
Studies on the effects of a novel intermittent therapy on intratumoral clonal architecture and resistance$410,835
R01 · FY2019 · CA · contact PI
Dissecting KRAS oncoprotein signaling with allele specific inhibitors$398,509
R01 · FY2019 · CA · contact PI
Elucidating the regulation of mitosis by BRAF V600E in lung cancer$152,355
K08 · FY2019 · CA · contact PI
Dissecting KRAS oncoprotein signaling with allele specific inhibitors$392,764
R01 · FY2018 · CA · contact PI
Elucidating the regulation of mitosis by BRAF V600E in lung cancer$180,036
K08 · FY2018 · CA · contact PI
Elucidating the regulation of mitosis by BRAF V600E in lung cancer$180,036
K08 · FY2017 · CA · contact PI
Elucidating the regulation of mitosis by BRAF V600E in lung cancer$180,036
K08 · FY2016 · CA · contact PI
Elucidating the regulation of mitosis by BRAF V600E in lung cancer$180,036
K08 · FY2015 · CA · contact PI